Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor-associated antigen presented by HLA-A2, HLA-A3, or HLA-A11
- Molecular classification
- Tumor-associated antigen, MHC class I ligand, Other
01
Overview
A tumor-associated antigen presented by HLA-A2, HLA-A3, or HLA-A11 refers to any peptide derived from tumor proteins that are displayed on the cell surface by one of these human leukocyte antigen (HLA) class I molecules. These complexes are recognized by cytotoxic CD8+ T cells, enabling targeted immune responses against tumor cells expressing these antigens. The actual identity of the antigen may differ widely; examples of such antigens (for HLA-A2 or HLA-A3) include MAGE-A3, beta-tubulin 5, CEA, HER-2/neu, and others[1][4][6]. Successfully targeting such antigens forms the basis of various immunotherapeutic strategies, including peptide vaccines and adoptive T cell therapies.
- Other names
- Tumor antigen (HLA-A2/A3/A11 restricted)Unspecified HLA class I-presented tumor antigen
02
Mechanism of action
Activation of cytotoxic T lymphocytes by antigen presentation Induction of immune response against antigen-expressing tumor cells
03
Biological functions
Immune response activationCell-mediated cytotoxicityAntigen presentationOther
04
Disease associations
CancerOther (in case these antigens are found in non-malignant tissues)
05
Safety considerations
On-target, off-tumor toxicity if the antigen is not strictly tumor-specificImmune escape (tumor antigen loss variants)HLA allele restriction limits patient eligibility
06
Interacting drugs
No single drug; varies by specific antigen. In general: antigen-specific vaccines, adoptive T cell therapies, immune checkpoint inhibitors in T cell therapy context
07
Biomarkers
HLA-A2, HLA-A3, HLA-A11 allele statusTumor expression of the specific antigen (when known)
Beyond the preview
Go deeper on Tumor-associated antigen presented by HLA-A2, HLA-A3, or HLA-A11.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tumor-associated antigen presented by HLA-A2, HLA-A3, or HLA-A11.